BIO-INNOVATION FOR HEALTH: SOUTH AFRICA

Transcription

1 BIO-INNOVATION FOR HEALTH: SOUTH AFRICA

2 SA s Burden of Disease SA MRC is committed to addressing the burden of disease that impacts health Cause of death Deaths % HIV/AIDS 180, Hypertensive heart disease 39, Lower respiratory infections 38, Cerebrovascular disease 37, Tuberculosis 37, Diarrhoeal diseases 26, Ischaemic heart disease 24, Interpersonal violence 20, Road injuries 18, Diabetes mellitus 13, COPD 11, Nephritis/nephrosis 9, Top 12 causes 457, Total 615, SAMRC 2015

3 Health Innovation Develop improved drugs to address priority diseases (incl. African Traditional Medicine); Develop new and improved vaccines and biologics; Develop new and improved diagnostics; Develop new and improved medical devices; Strengthen clinical research and development capabilities; Establish pharmaceutical manufacturing. DST2015 3

4 Health Value Chain DST2015 4

5 DRUG DISCOVERY AND DEVELOPMENT Target ID & Validation Lead Optimisation Medicinal chemistry Preclinical Development Clinical Trials Registration Manufacturing & distribution WADDP DST2015

6 Technology Transfer for local manufacturing DST2015

7 Strategic Health Innovation Partnerships Government Departments Funding Bodies NRF DoH DST DTI Universities MRC Research Institutes TIA IDC VCs SHIP R & D Science Councils ICGEB PPPs eg Biovac Local & International Private sector funders & Collaborators Private sector not for profit Aeras EDCTP MMV GATES FOUNDATION Private sector Pharmaceutical companies Small companies Platforms & service providers DST2015 7

8 PROJECT PORTFOLIO HIV TB Malaria NCD MCH Other Drugs Diagnostics Vaccines Targeting of HIV reservoirs Silver based microbicides Low dose duranovir trial Radio immunotherapy Genital Inflammation Test for HIV prevention Seq2Res for highthroughput, HIV drug resistance genotyping TB drug discovery consortium Bioinformatics for TB biomarker discovery TB CHAMP TB PROTEC SERS PoC urinary TB biomarkers device Rapid PCR diagnostic Novel HIV vaccine candidates Blood signature of TB infection HIV 1 Env 2dCD4S60C TB HART subunit vaccines T cell responses BNAbs, adjuvants and immunogens associated with protective TB immunity LTNPs andecs Systems immunology of Vaccine mediated effects in breakthrough infections vaccine induced protection against P5 contribution recurrent TB disease H3 D Malaria drug discovery platform Malaria transmission blocking group Mosquito parasite Infection Resource Centre Synthetic asphalathin for diabetes H3 D NCD drug discovery platform Novel PGM based drugs for cancer Pharmacogenomics & diagnostic for breast cancer Clinical exome sequencing for diabetes Early markers for diabetes in humans Sub lingual oxytocin trial Ebola diagnostic Devices / Platforms NHP Facility PUDAC Animal models for HIV vaccine development Production of CAP256 in plants Differential diagnosis of viral versus bacterial pneumonia at PoC Balloon Aortic Valvuloplasty (BAV) Catheter Umbiflow Mobile triage device and roll out E solutions to support community Healthcare SAMRC 2015

9 Malaria drug MMV 0048 Where we were in 2009? Med chemistry UCT in vivo DMPK CDCO in vitro DMPK CDCO in vitro Parasitology STPH in Vivo efficacy STPH SAMRC 2015

10 Where we are in 2015? Medicinal Chemistry in vitro DMPK UCT/H3D in vitro Parasitology in vivo DMPK UCT/H3D in Vivo efficacy STPH Tox PK API (2015) UCT/H3D UCT/H3D FIM SAMRC 2015

11 Some projects: Diagnostics and devices Febrile Diagnostic: Malaria Dengue Typhoid Leptospira Ebola TB Diagnostics Uterine Bleeding Tamponade SAMRC & DST 2015 Umbilical flow monitoring

12 Global Partnerships for local relevance Global Health Innovation Accelerator Partnership with PATH Launched August 2014 Affordable and appropriate medical devices, diagnostics and vaccines Focus on maternal and child health. Grand Challenges: South Africa Fund research causes of death in neonates and women during pregnancy, childbirth and in the early post partum period. Diagnostics, devices and clinical interventions that will lead to reductions in neonatal deaths. DST2015

13 WHY the SHIPs model Work together as equal partners Co-funding of projects Access to research infrastructure and key populations but on our terms Key research functions happen in country eg next generation sequencing Provide seed funding SHIP (end 2013) started with US$12million now US$70million Limit bureaucratic processes and allow quick decisionmaking processes From RFP to first payment: 6 months Provide linkages across government departments DST

14 Some SHIP Partners